Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy ...

H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3 from $3.50 and keeps a Buy rating on the shares following the Q4 ...

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Unicycive Therapeutics (UNCY) to $7.50 from $4 and keeps a Buy rating on the ...

HC Wainwright cut their FY2028 EPS estimates for shares of Gevo in a report released on Friday, March 28th. HC Wainwright ...

Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Acumen Pharmaceuticals ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

On Thursday, 27 March 2025, Blueprint Medicines (NASDAQ: BPMC) presented at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company outlined its growth ...